Drugs / [18F]3F-PHPG
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04510311 | Oct 2020 → Dec 2024 | neuroendocrine neoplasm | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02669563 | Dec 2015 → Aug 2016 | cardiomyopathy | University of Michigan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]3F-PHPG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02669563 ↗ |
| Known as | 3-[18F]Fluoro-para-hydroxyphenethylguanidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04510311 ↗ |
| Route | Intravenous | “IV injection of \[18F\]3F-PHPG” NCT02669563 ↗ |